Nigeria Takes Bold Step to End Malaria with Local Drugs

Nigeria is taking control of its malaria crisis by building the drugs it needs right at home.

The country carries 27% of the world's malaria burden and nearly one in three malaria deaths globally, according to the World Health Organization. Children under five face the greatest risk.

Emzor Pharmaceutical Industries announced this week that scaling local drug production and manufacturing Active Pharmaceutical Ingredients (APIs) are essential to ending the disease in Nigeria. The company marked World Malaria Day 2026 by calling for pharmaceutical independence.

"Local manufacturing is no longer optional. It is central to our national health security and the sustainability of malaria control efforts," said Uzoma Ezeoke, Executive Director at Emzor. The goal is producing high-quality, WHO-compliant antimalarials locally to close access gaps and protect against global supply disruptions.

Chairman Emeka Okoli described local API production as the "next frontier" in Nigeria's malaria fight. Manufacturing these core drug ingredients in-country would reduce reliance on imports, create jobs, and guarantee stricter quality control aligned with international standards.

Emzor has expanded access to WHO-compliant antimalarial medicines, including child-friendly dispersible formulations designed to improve treatment outcomes among young children. The company also emphasizes preventive therapies for pregnant women to reduce complications for mothers and babies.

The Ripple Effect

Nigeria's move toward pharmaceutical independence could transform healthcare across West Africa. By building local capacity to manufacture essential medicines, the country positions itself as a potential regional hub for drug production.

This shift means more than just fighting malaria. Local production creates stable jobs, strengthens supply chains, and ensures communities can access life-saving medicines even when global disruptions strike.

The approach also gives Nigeria control over quality standards and pricing, making treatments more affordable for families who need them most. When countries produce their own medicines, they protect their citizens from import delays and shortages.

Okoli emphasized the urgency of moving from planning to action. "With the right investments and partnerships, Nigeria can build a self-reliant pharmaceutical sector capable of ending malaria," he said.

Nigeria's plan shows how investing in local solutions creates lasting change for the world's most vulnerable populations.